Applied DNA Sciences (NASDAQ:APDN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the technology company’s stock.

Separately, HC Wainwright decreased their price objective on shares of Applied DNA Sciences from $2.00 to $1.50 and set a buy rating for the company in a research note on Friday, February 9th.

Applied DNA Sciences Stock Down 4.9 %

NASDAQ:APDN opened at $0.36 on Friday. The company has a fifty day simple moving average of $0.51 and a two-hundred day simple moving average of $0.69. The company has a market cap of $6.12 million, a price-to-earnings ratio of -0.67 and a beta of 0.07. Applied DNA Sciences has a 52 week low of $0.36 and a 52 week high of $1.86.

Applied DNA Sciences (NASDAQ:APDN) last issued its earnings results on Thursday, February 8th. The technology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.22. The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $0.70 million. Applied DNA Sciences had a negative net margin of 80.14% and a negative return on equity of 159.93%. On average, analysts expect that Applied DNA Sciences will post -0.63 EPS for the current year.

Hedge Funds Weigh In On Applied DNA Sciences

Several large investors have recently bought and sold shares of the stock. State Street Corp boosted its stake in Applied DNA Sciences by 53.6% in the first quarter. State Street Corp now owns 26,977 shares of the technology company’s stock valued at $58,000 after acquiring an additional 9,416 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Applied DNA Sciences by 3.4% in the third quarter. Vanguard Group Inc. now owns 523,691 shares of the technology company’s stock valued at $634,000 after buying an additional 17,241 shares during the last quarter. Atria Wealth Solutions Inc. raised its holdings in shares of Applied DNA Sciences by 32.2% in the fourth quarter. Atria Wealth Solutions Inc. now owns 83,110 shares of the technology company’s stock valued at $138,000 after buying an additional 20,250 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Applied DNA Sciences by 53.0% in the first quarter. Dimensional Fund Advisors LP now owns 65,916 shares of the technology company’s stock valued at $141,000 after buying an additional 22,843 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Applied DNA Sciences in the first quarter valued at about $49,000. Institutional investors and hedge funds own 22.22% of the company’s stock.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.